CNBC
02 Aug 2026, 20:00 UTC · 2h ago
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
02 Aug 2026, 20:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
AstraZeneca and Bristol Myers Squibb are considering a merger that would value the combined entity at approximately $400 billion. — A merger of this scale between two pharmaceutical giants would trigger massive volatility in their stock prices and significantly reshape the sector's competitive landscape.
+0.80The two companies have been in discussions regarding the merger over the last few months. — Indicates the deal has progressed beyond initial curiosity to a formal exploratory stage, increasing the probability of an announcement.
+0.40Which stocks this story touches
The company is considering a massive merger and the CFO expressed confidence in hitting a high revenue target.
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is in discussions for a potentially history-making merger with AstraZeneca.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
2h ago
